TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00313729
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03457389
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline tablet
Study: NCT02683109
Drug: FDC of tiotropium + olodaterol
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination of tiotropium + olodaterol
Study: NCT01451827
Drug: Tolvaptan MR
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50/80 mg capsules
Study: NCT01451827
Drug: Tolvaptan IR
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60/30 mg capsules
Study: NCT00620282
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Stepwise dose increase, s.c. (under the skin) injection, once daily
Study: NCT00620282
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 1 - 4 mg daily
Study: NCT01579500
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Subcutaneous injection of botulinum toxin type A
Study: NCT00831129
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg daily
Study: NCT00831129
Drug: Placebo Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tab daily
Study: NCT03572387
Drug: 5-Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneously on days 1-5 at a dose of 40 mg/m\^2
Study: NCT03572387
Drug: all trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg/m\^2, will be taken orally on days 3-7 of each cycle, divided into two doses
Study: NCT03572387
Drug: Lupron
Normalized name: Lupron
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg x 1
Study: NCT00707759
Drug: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone
Normalized name: Mycophenolate Mofetil
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone
Study: NCT00351663
Drug: Enoxaparine
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day
Study: NCT01038739
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 g per day
Study: NCT01038739
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 g per day
Study: NCT00003827
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003827
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003827
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02683109
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02683109
Drug: Olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02160236
Drug: tenoxicam
Normalized name: tenoxicam
DrugBank: Tenoxicam (DB00469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
Study: NCT02160236
Drug: serum physiologic
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
Study: NCT00664586
Drug: Terameprocol (EM-1421)
Normalized name: epinephrine
DrugBank: Terameprocol (DB12226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
Study: NCT00258713
Drug: voclosporin
Normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg BID
Study: NCT01421043
Drug: triazolam liquid oral drops
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg single dose oral drops
Study: NCT01421043
Drug: triazolam tablets
Normalized name: Triazolam Tablets
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg single oral dose
Study: NCT03152565
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity.
Study: NCT01017120
Drug: Tazarotene Foam
Normalized name: tazarotene Topical Foam
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene foam once a day application to the face
Study: NCT00509431
Drug: Erlotinib + Sirolimus
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
Study: NCT00160602
Drug: Certolizumab Pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01993927
Drug: Voglibose
Normalized name: Voglibose
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Voglibose Tablets / Voglibose OD Tablets
Study: NCT01017120
Drug: Vehicle Foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Foam once a day application to the face
Study: NCT00157586
Drug: Delapril, Delapril-Manidipine Fixed combination
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03192657
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The first administration should be within 8 weeks after disease onset.
Study: NCT00759005
Drug: propranolol and cortisol
Normalized name: propranolol and thiazides
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03535363
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Osimertinib 80mg or 40mg
Study: NCT03013400
Drug: Ebselen
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
Study: NCT00760474
Drug: Pregabalin, then placebo
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
Study: NCT00760474
Drug: Placebo, then pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
Study: NCT02877888
Drug: fluoride varnish 22600ppm
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application on teeth every 6months
Study: NCT00080678
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00080678
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02484053
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
Study: NCT03290430
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
Study: NCT00283179
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00283179
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00126230
Drug: docetaxel and samarium
Normalized name: samarium
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00093483
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV over 1 hour on day 1
Study: NCT00093483
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV over 1 hour every 12 hours on days 1-6
Study: NCT00093483
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
Study: NCT01272128
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
Study: NCT02008877
Drug: ganetespib
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
Study: NCT02008877
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
Study: NCT03760445
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg or 1000 mg or other strengths as locally available given intravenously
Study: NCT03760445
Drug: midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25mg capsules given orally
Study: NCT03760445
Drug: liposomal cytarabine/daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/44mg or other strength as locally available given intravenously
Study: NCT03760445
Drug: posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg delayed release tablet or other strength as locally available given orally
Study: NCT03760445
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg/mL oral solution or in other strength as locally available
Study: NCT03656952
Drug: PF-06700841
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of 200 mg PF-06700841
Study: NCT03656952
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single oral dose of 400 mg moxifloxacin
Study: NCT00337259
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
Study: NCT04606303
Drug: Toripalimab combination with platinum-containing dual-drug chemotherapy.
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1), or gemcitabine 1250mg/m2 (D1, D8), or Pemetroxel 500mg/m2 (D1)), Toripalimab 240mg D1, Q3W.~If the patient is SD or PD, Toripalimab combined with platinum-containing dual-drug chemotherapy in the third cycle will continue, and a total of 4 cycles can be carried out at most, and the therapeutic effect will be evaluated after each cycle of treatment. If the patient is PR or CR at any time during the treatment (after treatment in the third or fourth cycle), the surgical treatment will be entered. If PR or CR is still not reached after treatment in the fourth cycle, the endpoint of the trial will be reached, theobservation of the patient will be finished, and the subsequent treatment will be decided by the clinician.
Study: NCT00327223
Drug: imexon
Normalized name: Imexon
DrugBank: Imexon (DB05003)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03485534
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Viread 300mg
Study: NCT03485534
Drug: Tenofovir Disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virehepa 245mg
Study: NCT02506517
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00914901
Drug: inhaled salmeterol
Normalized name: salmeterol Inhalant Product
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhalation of 100 micrograms salmeterol in one dose.
Study: NCT01450813
Drug: Rocuronium 0.2 mg/kg
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion x1 prior to laryngoscopy
Study: NCT01450813
Drug: Rocuronium 0.4 mg/kg
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion x1 prior to laryngoscopy
Study: NCT01450813
Drug: Rocuronium 0.6 mg/kg
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion x1 prior to laryngoscopy
Study: NCT00152984
Drug: Tiotropium inhalation capsules
Normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01891201
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
Study: NCT00653523
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10 mg once daily
Study: NCT00856037
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00057031
Drug: DN-101 (calcitriol)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01330043
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study: NCT01330043
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study: NCT01330043
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
Study: NCT03976310
Drug: 48 weeks of Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
Study: NCT01625338
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01625338
Drug: Peg-IFN
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-IFN 180 μg administered once weekly by subcutaneous injection
Study: NCT00040027
Drug: thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00040027
Drug: placebo + PEGinterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00806624
Drug: DU-176b tablets
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-176b tablets taken once daily for up to 3 months
Study: NCT00806624
Drug: Warfarin tablets
Normalized name: warfarin Oral Tablet
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin tablets taken once daily for up to 3 months
Study: NCT02757729
Drug: PAC-14028 cream 0.1%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02757729
Drug: PAC-14028 cream 0.3%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02757729
Drug: PAC-14028 cream 1.0%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02760498
Drug: cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02757729
Drug: PAC-14028 cream vehicle
Normalized name: PAC-14028
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02972983
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant therapy for up to five days
Study: NCT01935089
Drug: Pegylated Interferon alpha 2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1µg/kg/week
Study: NCT01309386
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
Study: NCT01309386
Drug: Morphine SR
Normalized name: Ratio-Morphine SR
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
Study: NCT00737100
Drug: Tiotropium bromide 5 mcg
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient to recieve high dose tiotropium once daily
Study: NCT00737100
Drug: tiotropium bromide-low dose-2.5mcg
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient to receive low dose tiotropium once daily
Study: NCT02571140
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous standard injection
Study: NCT02571140
Drug: Oral PTH (1-34)
Normalized name: PTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different optimization of API
Study: NCT01240096
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine 15 mg daily